Perspectives on prehypertension.

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The Trial of Preventing Hypertension (TROPHY) investigated pharmacologic intervention in patients with prehypertension. TROPHY confirmed that treatment with candesartan 16 mg can prevent or postpone the development of hypertension, demonstrating a 66.3% reduction in hypertension incidence relative to placebo (26.8% absolute reduction) at 2 years, and a 15.6% reduction in hypertension incidence relative to placebo (9.8% absolute reduction) at 4 years. Further analyses of TROPHY may help to delineate the mechanisms behind this result more specifically, including those relating to components of the metabolic syndrome and markers of inflammation and early vascular change. The rate of progression and the concurrence of risk factors make a strong case for the development of a directive for closer follow-up and treatment. The potential for success in reducing cardiovascular events is great, given the prevalence of prehypertension and the likelihood of progression.

Original languageEnglish (US)
Pages (from-to)364-365
Number of pages2
JournalJournal of the CardioMetabolic Syndrome
Volume1
Issue number5
StatePublished - Sep 2006

Fingerprint

Prehypertension
Hypertension
Placebos
Incidence
Blood Vessels
Inflammation
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Perspectives on prehypertension. / Nesbitt, Shawna D.

In: Journal of the CardioMetabolic Syndrome, Vol. 1, No. 5, 09.2006, p. 364-365.

Research output: Contribution to journalArticle

@article{33693b7b368b4ea1b4308b1fb6e9de5e,
title = "Perspectives on prehypertension.",
abstract = "The Trial of Preventing Hypertension (TROPHY) investigated pharmacologic intervention in patients with prehypertension. TROPHY confirmed that treatment with candesartan 16 mg can prevent or postpone the development of hypertension, demonstrating a 66.3{\%} reduction in hypertension incidence relative to placebo (26.8{\%} absolute reduction) at 2 years, and a 15.6{\%} reduction in hypertension incidence relative to placebo (9.8{\%} absolute reduction) at 4 years. Further analyses of TROPHY may help to delineate the mechanisms behind this result more specifically, including those relating to components of the metabolic syndrome and markers of inflammation and early vascular change. The rate of progression and the concurrence of risk factors make a strong case for the development of a directive for closer follow-up and treatment. The potential for success in reducing cardiovascular events is great, given the prevalence of prehypertension and the likelihood of progression.",
author = "Nesbitt, {Shawna D.}",
year = "2006",
month = "9",
language = "English (US)",
volume = "1",
pages = "364--365",
journal = "Journal of the CardioMetabolic Syndrome",
issn = "1559-4564",
publisher = "Le Jacq Ltd.",
number = "5",

}

TY - JOUR

T1 - Perspectives on prehypertension.

AU - Nesbitt, Shawna D.

PY - 2006/9

Y1 - 2006/9

N2 - The Trial of Preventing Hypertension (TROPHY) investigated pharmacologic intervention in patients with prehypertension. TROPHY confirmed that treatment with candesartan 16 mg can prevent or postpone the development of hypertension, demonstrating a 66.3% reduction in hypertension incidence relative to placebo (26.8% absolute reduction) at 2 years, and a 15.6% reduction in hypertension incidence relative to placebo (9.8% absolute reduction) at 4 years. Further analyses of TROPHY may help to delineate the mechanisms behind this result more specifically, including those relating to components of the metabolic syndrome and markers of inflammation and early vascular change. The rate of progression and the concurrence of risk factors make a strong case for the development of a directive for closer follow-up and treatment. The potential for success in reducing cardiovascular events is great, given the prevalence of prehypertension and the likelihood of progression.

AB - The Trial of Preventing Hypertension (TROPHY) investigated pharmacologic intervention in patients with prehypertension. TROPHY confirmed that treatment with candesartan 16 mg can prevent or postpone the development of hypertension, demonstrating a 66.3% reduction in hypertension incidence relative to placebo (26.8% absolute reduction) at 2 years, and a 15.6% reduction in hypertension incidence relative to placebo (9.8% absolute reduction) at 4 years. Further analyses of TROPHY may help to delineate the mechanisms behind this result more specifically, including those relating to components of the metabolic syndrome and markers of inflammation and early vascular change. The rate of progression and the concurrence of risk factors make a strong case for the development of a directive for closer follow-up and treatment. The potential for success in reducing cardiovascular events is great, given the prevalence of prehypertension and the likelihood of progression.

UR - http://www.scopus.com/inward/record.url?scp=34548092708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548092708&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 364

EP - 365

JO - Journal of the CardioMetabolic Syndrome

JF - Journal of the CardioMetabolic Syndrome

SN - 1559-4564

IS - 5

ER -